Savara (SVRA) Accumulated Expenses (2010 - 2026)
Savara (SVRA) reported Accumulated Expenses of $11.0 million for Q1 2026, up 979.47% year-over-year from $1.0 million in Q1 2025, and up 68.54% on a QoQ basis from $6.6 million in Q4 2025.
Savara (SVRA) has 17 years of Accumulated Expenses data on file, last reported at $11.0 million in Q1 2026.
- Quarterly Accumulated Expenses rose 979.47% year-over-year to $11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (up 979.47% YoY) and the FY2025 annual result came in at $6.6 million, up 30.6% from the prior year.
- Accumulated Expenses climbed to $11.0 million in Q1 2026 per SVRA's latest filing, from $6.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $12.6 million in Q3 2025 and bottomed at $1.0 million in Q1 2025.
- The 5-year median for Accumulated Expenses is $5.0 million (2024), against an average of $5.3 million.
- The widest annual swing landed in 2025, when Accumulated Expenses plunged 85.3%; it then surged 979.47% in 2026.
- Tracing SVRA's Accumulated Expenses over 5 years: stood at $2.4 million in 2022, then soared by 199.92% to $7.1 million in 2023, then decreased by 29.27% to $5.0 million in 2024, then jumped by 30.6% to $6.6 million in 2025, then soared by 68.54% to $11.0 million in 2026.
- Per Business Quant, the three latest SVRA Accumulated Expenses figures stand at $11.0 million (Q1 2026), $6.6 million (Q4 2025), and $12.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.04 Mn |
| Dec 31, 2025 | 6.55 Mn |
| Sep 30, 2025 | 12.62 Mn |
| Jun 30, 2025 | 8.88 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 8.18 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 6.96 Mn |
| Dec 31, 2023 | 7.09 Mn |
| Sep 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 3.35 Mn |
| Dec 31, 2022 | 2.37 Mn |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 2.53 Mn |
| Dec 31, 2021 | 4.88 Mn |
| Sep 30, 2021 | 5.22 Mn |
| Jun 30, 2021 | 3.49 Mn |
| Mar 31, 2021 | 1.07 Mn |
| Dec 31, 2020 | 1.92 Mn |
| Sep 30, 2020 | 5.89 Mn |
| Jun 30, 2020 | 4.45 Mn |
| Mar 31, 2020 | 705,000.00 |
| Dec 31, 2019 | 5.47 Mn |
| Sep 30, 2019 | 5.39 Mn |
| Jun 30, 2019 | 4.61 Mn |
| Mar 31, 2019 | 392,000.00 |
| Dec 31, 2018 | 3.38 Mn |
| Sep 30, 2018 | 388,000.00 |
| Jun 30, 2018 | 2.80 Mn |
| Mar 31, 2018 | 227,000.00 |
| Dec 31, 2017 | 2.97 Mn |
| Sep 30, 2017 | 157,000.00 |
| Jun 30, 2017 | 527,000.00 |
| Mar 31, 2017 | 25,000.00 |
| Dec 31, 2016 | 2.48 Mn |
| Sep 30, 2016 | 6.60 Mn |
| Jun 30, 2016 | 8.40 Mn |
| Mar 31, 2016 | 976,000.00 |
| Dec 31, 2015 | 8.15 Mn |
| Sep 30, 2015 | 7.31 Mn |
| Jun 30, 2015 | 950,000.00 |
| Mar 31, 2015 | 799,000.00 |
| Dec 31, 2014 | 5.38 Mn |
| Sep 30, 2014 | 1.51 Mn |
| Jun 30, 2014 | 3.48 Mn |
| Mar 31, 2014 | 3.55 Mn |
| Dec 31, 2013 | 2.27 Mn |
| Sep 30, 2013 | 2.16 Mn |
| Jun 30, 2013 | 799,061.00 |
| Mar 31, 2013 | 555,065.00 |
| Dec 31, 2012 | 445,352.00 |
| Sep 30, 2012 | 825,800.00 |
| Jun 30, 2012 | 661,447.00 |
| Mar 31, 2012 | 986,093.00 |
| Dec 31, 2011 | 756,773.00 |
| Sep 30, 2011 | 675,715.00 |
| Jun 30, 2011 | 1.08 Mn |
| Dec 31, 2010 | 456,839.00 |